Trulieve Cannabis Corp. has quickly become one of the most closely followed names in the U.S. cannabis sector after making history in mid-2026 as the first domestic marijuana company to list on the New York Stock Exchange. That uplisting, which followed the federal rescheduling of medical cannabis to Schedule III, drew a wave of fresh analyst coverage. Notably, Cantor Fitzgerald initiated coverage with an Overweight rating and a $15 price target, and $15 also represents the low end of the broader analyst range, which spans roughly $15 to $21. For investors searching for a realistic near-term objective, $15 sits just above the stock's 52-week high and stands out as a natural psychological milestone.
Trulieve is a Florida-based, vertically integrated medical cannabis operator that cultivates, processes, and sells its products through its own dispensaries and home delivery. It operates across states including Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. The company generated about $1.18 billion in revenue in 2025 and reported second-quarter 2026 revenue of roughly $271 million, with adjusted earnings per share (EPS) of $0.11 that beat consensus estimates of $0.03.
Fundamentals remain mixed. Trulieve delivered a 60% gross margin and reported operating cash flow of approximately $109 million and free cash flow of about $74 million in the first half of 2026, but it still posts a net loss and carries no dividend. The shares, with a market capitalization near $2.1 billion, have traded in a wide 52-week range of approximately $4.62 to $13.28, reflecting the sector's elevated volatility.
Several catalysts support the case for a move toward $15. The NYSE listing meaningfully expanded Trulieve's institutional investor base and improved its access to capital, a step that historically accompanies higher valuations. The Schedule III rescheduling removes a major overhang for U.S. cannabis operators by easing certain tax and banking constraints. Trulieve's continued expansion, including the launch of Georgia's expanded medical program, provides a growth runway, while a recently announced share repurchase program signals management confidence in the company's value. Positive free cash flow also distinguishes Trulieve from many peers that continue to burn cash.
The path to $15 is not without obstacles. Despite improving operations, Trulieve remains unprofitable on a net-income basis, and the company's financial forecasts suggest revenue may decline modestly in the near term. The broader cannabis industry still faces fragmented state-level regulation and uncertainty over the pace of further federal reform. The stock's high beta and wide trading range mean sharp drawdowns can occur quickly, and any setback in Florida's market dynamics—Trulieve's most important state—could pressure sentiment. Clearing the prior high near $13.28 will require sustained buying interest and continued execution.
Wall Street's view is decidedly optimistic. According to data aggregators, analysts polled by S&P Global rate Trulieve a consensus Strong Buy, with an average 12-month price target of roughly $18.18. Individual targets range from $15 (Cantor Fitzgerald) to $21, with firms such as Alliance Global Partners and Canaccord Genuity carrying $20 targets and Roth MKM at $19. This means the $15 milestone sits comfortably below the consensus forecast, suggesting most analysts see it as an achievable interim level rather than a stretch goal.
From a technical perspective, the 52-week high near $13.28 is the first major resistance level that must be overcome before $15 enters play. Because $15 is also a round, psychologically significant number that sits above all recent trading, it is likely to attract selling pressure from investors looking to lock in gains. On the downside, the $9–10 zone has served as recent support, with the 52-week low near $4.62 marking the extreme risk level. The stock's overall trend remains constructive after its uplisting-driven rally, but the distance between current prices and $15 still requires roughly one-third to two-fifths of additional upside.
For traders monitoring whether Trulieve can sustain momentum toward higher levels, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to track shifting conditions. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify changing market trends more efficiently than manual screening alone.
Trulieve reaching $15 is a plausible but not guaranteed outcome. The strongest supporting factors—the historic NYSE listing, Schedule III rescheduling, positive free cash flow, and a consensus analyst target well above $15—suggest the stock has a credible foundation for further gains. However, the primary risks, including persistent net losses, regulatory uncertainty, and the need to clear the $13.28 prior high, cannot be ignored. Investors should monitor quarterly execution, cash-flow trends, and any developments in federal cannabis policy as the key signals for whether the $15 price target becomes achievable in the months ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TRLV has been closely correlated with GLAS. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if TRLV jumps, then GLAS could also see price increases.
| Ticker / NAME | Correlation To TRLV | 1D Price Change % | ||
|---|---|---|---|---|
| TRLV | 100% | -0.09% | ||
| GLAS - TRLV | 72% Closely correlated | -0.63% | ||
| CGC - TRLV | 69% Closely correlated | -0.25% | ||
| ACB - TRLV | 65% Loosely correlated | +0.27% | ||
| CRON - TRLV | 61% Loosely correlated | -0.63% | ||
| OGI - TRLV | 54% Loosely correlated | -1.87% | ||
More | ||||